XELOX doublet regimen versus EOX triplet regimen as first‐line treatment for advanced gastric cancer: An open‐labeled, multicenter, randomized, prospective phase III trial (EXELOX)

Abstract Background There is no consensus on whether triplet regimen is better than doublet regimen in the first‐line treatment of advanced gastric cancer (AGC). We aimed to compare the efficacy and safety of oxaliplatin plus capecitabine (XELOX) and epirubicin, oxaliplatin, plus capecitabine (EOX)...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	Xiao‐Dong Zhu, Ming‐Zhu Huang, Yu‐Sheng Wang, Wan‐Jing Feng, Zhi‐Yu Chen, Yi‐Fu He, Xiao‐Wei Zhang, Xin Liu, Chen‐Chen Wang, Wen Zhang, Jie‐Er Ying, Jun Wu, Lei Yang, Yan‐Ru Qin, Jian‐Feng Luo, Xiao‐Ying Zhao, Wen‐Hua Li, Zhe Zhang, Li‐Xin Qiu, Qi‐Rong Geng, Jian‐Ling Zou, Jie‐Yun Zhang, Hong Zheng, Xue‐Feng Song, Shu‐Sheng Wu, Cheng‐Yan Zhang, Zhe Gong, Qin‐Qin Liu, Xiao‐Feng Wang, Qi Xu, Qi Wang, Jian‐Mei Ji, Jian Zhao, Wei‐Jian Guo
Format:	Artigo
Sprog:	Inglês
Udgivet:	Wiley 2022-04-01
Serier:	Cancer Communications
Fag:	Advanced gastric cancer, chemotherapy, XELOX doublet regimen EOX triplet regimen, non‐inferiority, quality of life, phase III trial
Online adgang:	https://doi.org/10.1002/cac2.12278
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!